Consensus Enfusion, Inc.

Equities

ENFN

US2928121043

Market Closed - Nyse Other stock markets 21:00:02 09/05/2024 BST			5-day change	1st Jan Change
9.26 ^USD	-5.22%		-2.73%	-4.54%

05-09	Enfusion Shares Fall Despite Higher Q1 Results	MT
03-14	Enfusion Shares Slip After Short-Seller Spruce Point Warns of 'Financial Restatement Risk'	MT

Evolution of the average Target Price on Enfusion, Inc.

Price target over the last 5 years

History of analyst recommendation changes

cb773f40e7fe181f631479d978.eUJVkNbMy2mhZuZ6c59A2FUJja5xgHQ525duqy7MPXU.Cgsbo5uvjwuYH5c2OeksmSJ95ekI5xl9nNQnz1y0BDw2ATPKg46dLMoPvw~19ab495fabc5738e835a33c1e48e1ade

Analyst Recommendations on Enfusion, Inc.

BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating	03-13	MT
Goldman Sachs Downgrades Enfusion to Sell From Neutral, Trims Price Target to $8 From $9	02-28	MT
JPMorgan Downgrades Enfusion to Underweight From Neutral, Cut Price Target to $9 From $11	01-30	MT
UBS Adjusts Enfusion Price Target to $9.50 From $9, Maintains Neutral Rating	11-08	MT
UBS Initiates Coverage on Enfusion With Neutral Rating, $9 Price Target	11-07	MT
Goldman Sachs Adjusts Enfusion's Price Target to $10 From $11.50, Keeps Neutral Rating	09/08/23	MT
Morgan Stanley Adjusts Enfusion Price Target to $11 From $12, Maintains Overweight Rating	09/08/23	MT
Piper Sandler Adjusts Price Target on Enfusion to $9 From $11, Maintains Neutral Rating	22/05/23	MT
Credit Suisse Trims Enfusion's Price Target to $11 From $14, Keeps Neutral Rating	10/05/23	MT
Piper Sandler Starts Enfusion at Neutral With $11 Price Target	03/04/23	MT
JPMorgan Starts Enfusion at Neutral With $12 Price Target	15/03/23	MT
Goldman Sachs Adjusts Price Target on Enfusion to $11.50 From $9.50, Maintains Neutral Rating	08/03/23	MT
Goldman Sachs Adjusts Price Target on Enfusion to $9.50 From $14, Maintains Neutral Rating	26/01/23	MT
BofA Downgrades Enfusion to Underperform From Neutral, Trims Price Target to $10 From $15	04/01/23	MT
Morgan Stanley Upgrades Enfusion to Overweight From Equalweight, Adjusts Price Target to $12 From $13	03/01/23	MT
Goldman Sachs Adjusts Price Target on Enfusion to $14 From $13, Maintains Neutral Rating	11/11/22	MT
BofA Securities Downgrades Enfusion to Neutral From Buy, Adjusts Price Target to $15 From $17	03/10/22	MT
Goldman Sachs Adjusts Enfusion's Price Target to $13 From $12, Maintains Neutral Rating	10/08/22	MT
Morgan Stanley Raises Enfusion's Price Target to $13 From $8, Maintains Equalweight Rating	10/08/22	MT
Goldman Sachs Lowers Enfusion's Price Target to $12 From $14, Neutral Rating Kept	14/07/22	MT
Piper Sandler Adjusts Enfusion's Price Target to $12 from $15, Keeps Overweight Rating	06/07/22	MT
Credit Suisse Lowers Neutral-Rated Enfusion's Price Target to $13 from $16 Given Recent Market Volatility, Multiple Compression Across Sector	16/05/22	MT
Credit Suisse Adjusts Enfusion's Price Target to $16 from $20, Keeps Neutral Rating	13/05/22	MT
Morgan Stanley Lowers Enfusion's Price Target to $8 From $18, Maintains Equalweight Rating	13/05/22	MT
Goldman Sachs Adjusts Enfusion Price Target to $16 From $15, Maintains Neutral Rating	25/03/22	MT